BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Schaedel C, de Monestrol I, Hjelte L, Johannesson M, Kornfält R, Lindblad A, Strandvik B, Wahlgren L, Holmberg L. Predictors of deterioration of lung function in cystic fibrosis*: CFTR Genotype in Lung Function in CF. Pediatr Pulmonol 2002;33:483-91. [DOI: 10.1002/ppul.10100] [Cited by in Crossref: 129] [Cited by in F6Publishing: 119] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Griffin PE, Roddam LF, Belessis YC, Strachan R, Beggs S, Jaffe A, Cooley MA. Expression of PPARγ and paraoxonase 2 correlated with Pseudomonas aeruginosa infection in cystic fibrosis. PLoS One 2012;7:e42241. [PMID: 22860094 DOI: 10.1371/journal.pone.0042241] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
2 Skopelja S, Hamilton BJ, Jones JD, Yang ML, Mamula M, Ashare A, Gifford AH, Rigby WF. The role for neutrophil extracellular traps in cystic fibrosis autoimmunity. JCI Insight 2016;1:e88912. [PMID: 27777975 DOI: 10.1172/jci.insight.88912] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 7.5] [Reference Citation Analysis]
3 Que C, Cullinan P, Geddes D. Improving rate of decline of FEV1 in young adults with cystic fibrosis. Thorax 2006;61:155-7. [PMID: 16384880 DOI: 10.1136/thx.2005.043372] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 4.6] [Reference Citation Analysis]
4 Pittman JE, Ferkol TW. The Evolution of Cystic Fibrosis Care. Chest 2015;148:533-42. [PMID: 25764168 DOI: 10.1378/chest.14-1997] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
5 Pittman JE, Calloway EH, Kiser M, Yeatts J, Davis SD, Drumm ML, Schechter MS, Leigh MW, Emond M, Van Rie A, Knowles MR. Age of Pseudomonas aeruginosa acquisition and subsequent severity of cystic fibrosis lung disease. Pediatr Pulmonol 2011;46:497-504. [PMID: 21194167 DOI: 10.1002/ppul.21397] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
6 Luettich K, Sharma M, Yepiskoposyan H, Breheny D, Lowe FJ. An Adverse Outcome Pathway for Decreased Lung Function Focusing on Mechanisms of Impaired Mucociliary Clearance Following Inhalation Exposure. Front Toxicol 2021;3:750254. [PMID: 35295103 DOI: 10.3389/ftox.2021.750254] [Reference Citation Analysis]
7 Earnest A, Salimi F, Wainwright CE, Bell SC, Ruseckaite R, Ranger T, Kotsimbos T, Ahern S. Lung function over the life course of paediatric and adult patients with cystic fibrosis from a large multi-centre registry. Sci Rep 2020;10:17421. [PMID: 33060788 DOI: 10.1038/s41598-020-74502-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
8 Hauser AR, Jain M, Bar-Meir M, McColley SA. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin Microbiol Rev 2011;24:29-70. [PMID: 21233507 DOI: 10.1128/CMR.00036-10] [Cited by in Crossref: 259] [Cited by in F6Publishing: 150] [Article Influence: 23.5] [Reference Citation Analysis]
9 Olszowiec-Chlebna M, Koniarek-Maniecka A, Stelmach W, Smejda K, Jerzyńska J, Majak P, Białas M, Stelmach I. Predictors of deterioration of lung function in Polish children with cystic fibrosis. Arch Med Sci 2016;12:402-7. [PMID: 27186187 DOI: 10.5114/aoms.2016.59268] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
10 Carlsson M, Eriksson L, Pressler T, Kornfält R, Mared L, Meyer P, Wiik A, Wieslander J, Segelmark M. Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis. J Cyst Fibros 2007;6:228-33. [PMID: 17166780 DOI: 10.1016/j.jcf.2006.10.005] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
11 Martín-Frías M, Máiz L, Carcavilla A, Barrio R. Long-term benefits in lung function and nutritional status of strict metabolic control of cystic fibrosis-related diabetes. Arch Bronconeumol 2011;47:531-4. [PMID: 21798655 DOI: 10.1016/j.arbres.2011.06.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Wennström I, Isberg P, Wirtberg I, Rydén O. From children to young adults: cystic fibrosis and siblingship A longitudinal study: From children to young adults: CF and siblingship. Acta Paediatrica 2011;100:1048-53. [DOI: 10.1111/j.1651-2227.2011.02182.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
13 Costa M, Potvin S, Berthiaume Y, Gauthier L, Jeanneret A, Lavoie A, Levesque R, Chiasson J, Rabasa-lhoret R. Diabetes: a major co-morbidity of cystic fibrosis. Diabetes & Metabolism 2005;31:221-32. [DOI: 10.1016/s1262-3636(07)70189-1] [Cited by in Crossref: 73] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
14 Konstan MW, McKone EF, Moss RB, Marigowda G, Tian S, Waltz D, Huang X, Lubarsky B, Rubin J, Millar SJ, Pasta DJ, Mayer-Hamblett N, Goss CH, Morgan W, Sawicki GS. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet Respir Med. 2017;5:107-118. [PMID: 28011037 DOI: 10.1016/s2213-2600(16)30427-1] [Cited by in Crossref: 148] [Cited by in F6Publishing: 56] [Article Influence: 24.7] [Reference Citation Analysis]
15 Schiaffini R, Brufani C, Russo B, Fintini D, Migliaccio A, Pecorelli L, Bizzarri C, Lucidi V, Cappa M. Abnormal glucose tolerance in children with cystic fibrosis: the predictive role of continuous glucose monitoring system. European Journal of Endocrinology 2010;162:705-10. [DOI: 10.1530/eje-09-1020] [Cited by in Crossref: 41] [Cited by in F6Publishing: 10] [Article Influence: 3.4] [Reference Citation Analysis]
16 Kraemer R, Baldwin DN, Ammann RA, Frey U, Gallati S. Progression of pulmonary hyperinflation and trapped gas associated with genetic and environmental factors in children with cystic fibrosis. Respir Res 2006;7:138. [PMID: 17137500 DOI: 10.1186/1465-9921-7-138] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
17 Patton SR, Dolan LM, Mitchell MJ, Byars KC, Standiford D, Powers SW. Mealtime interactions in families of pre-schoolers with type 1 diabetes. Pediatr Diabetes 2004;5:190-8. [DOI: 10.1111/j.1399-543x.2004.00058.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
18 Konstan MW, Wagener JS, Vandevanter DR, Pasta DJ, Yegin A, Rasouliyan L, Morgan WJ. Risk factors for rate of decline in FEV1 in adults with cystic fibrosis. J Cyst Fibros 2012;11:405-11. [PMID: 22561369 DOI: 10.1016/j.jcf.2012.03.009] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 7.2] [Reference Citation Analysis]
19 Abbott L, Plummer A, Hoo ZH, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst Rev 2019;9:CD006682. [PMID: 31487382 DOI: 10.1002/14651858.CD006682.pub6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
20 Rosenfeld M, Emerson J, McNamara S, Joubran K, Retsch-Bogart G, Graff GR, Gutierrez HH, Kanga JF, Lahiri T, Noyes B, Ramsey B, Ren CL, Schechter M, Morgan W, Gibson RL; EPIC Study Group Participating Clinical Sites. Baseline characteristics and factors associated with nutritional and pulmonary status at enrollment in the cystic fibrosis EPIC observational cohort. Pediatr Pulmonol 2010;45:934-44. [PMID: 20597081 DOI: 10.1002/ppul.21279] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 3.3] [Reference Citation Analysis]
21 Young RL, Malcolm KC, Kret JE, Caceres SM, Poch KR, Nichols DP, Taylor-Cousar JL, Saavedra MT, Randell SH, Vasil ML. Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR. PLoS One. 2011;6:e23637. [PMID: 21909403 DOI: 10.1371/journal.pone.0023637] [Cited by in Crossref: 138] [Cited by in F6Publishing: 135] [Article Influence: 12.5] [Reference Citation Analysis]
22 Nair CG, Chao C, Ryall B, Williams HD. Sub-lethal concentrations of antibiotics increase mutation frequency in the cystic fibrosis pathogen Pseudomonas aeruginosa. Lett Appl Microbiol 2013;56:149-54. [PMID: 23206221 DOI: 10.1111/lam.12032] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.2] [Reference Citation Analysis]
23 Street ME, Spaggiari C, Ziveri MA, Rossi M, Volta C, Viani I, Grzincich GL, Sartori C, Zanzucchi M, Raia V, Terzi C, Pisi G, Zanetti E, Boguszewski MC, Kamoi TO, Bernasconi S. Insulin production and resistance in cystic fibrosis: effect of age, disease activity, and genotype. J Endocrinol Invest 2012;35:246-53. [PMID: 21483232 DOI: 10.3275/7628] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
24 Riethmueller J, Ballmann M, Schroeter TW, Franke P, von Butler R, Claass A, Junge S, Doering G, Stern M; German Multicenter Study Group. Tobramycin once- vs thrice-daily for elective intravenous antipseudomonal therapy in pediatric cystic fibrosis patients. Infection 2009;37:424-31. [DOI: 10.1007/s15010-009-8117-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
25 Clark ST, Diaz Caballero J, Cheang M, Coburn B, Wang PW, Donaldson SL, Zhang Y, Liu M, Keshavjee S, Yau YC, Waters VJ, Elizabeth Tullis D, Guttman DS, Hwang DM. Phenotypic diversity within a Pseudomonas aeruginosa population infecting an adult with cystic fibrosis. Sci Rep 2015;5:10932. [PMID: 26047320 DOI: 10.1038/srep10932] [Cited by in Crossref: 61] [Cited by in F6Publishing: 59] [Article Influence: 8.7] [Reference Citation Analysis]
26 Lindberg U, Carlsson M, Löfdahl CG, Segelmark M. BPI-ANCA and long-term prognosis among 46 adult CF patients: a prospective 10-year follow-up study. Clin Dev Immunol 2012;2012:370107. [PMID: 23346184 DOI: 10.1155/2012/370107] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
27 Belkin RA, Henig NR, Singer LG, Chaparro C, Rubenstein RC, Xie SX, Yee JY, Kotloff RM, Lipson DA, Bunin GR. Risk factors for death of patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 2006;173:659-66. [PMID: 16387803 DOI: 10.1164/rccm.200410-1369OC] [Cited by in Crossref: 113] [Cited by in F6Publishing: 43] [Article Influence: 6.6] [Reference Citation Analysis]
28 Plummer A, Wildman M, Gleeson T. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst Rev 2016;9:CD006682. [PMID: 27582394 DOI: 10.1002/14651858.CD006682.pub5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
29 Sawicki GS, Mckone EF, Pasta DJ, Millar SJ, Wagener JS, Johnson CA, Konstan MW. Sustained Benefit from Ivacaftor Demonstrated by Combining Clinical Trial and Cystic Fibrosis Patient Registry Data. Am J Respir Crit Care Med 2015;192:836-42. [DOI: 10.1164/rccm.201503-0578oc] [Cited by in Crossref: 157] [Cited by in F6Publishing: 49] [Article Influence: 22.4] [Reference Citation Analysis]
30 Laube BL, Carson KA, Evans CM, Richardson VL, Sharpless G, Zeitlin PL, Mogayzel PJ Jr. Changes in mucociliary clearance over time in children with cystic fibrosis. Pediatr Pulmonol 2020;55:2307-14. [PMID: 32427408 DOI: 10.1002/ppul.24858] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
31 Hunter RC, Klepac-ceraj V, Lorenzi MM, Grotzinger H, Martin TR, Newman DK. Phenazine Content in the Cystic Fibrosis Respiratory Tract Negatively Correlates with Lung Function and Microbial Complexity. Am J Respir Cell Mol Biol 2012;47:738-45. [DOI: 10.1165/rcmb.2012-0088oc] [Cited by in Crossref: 127] [Cited by in F6Publishing: 81] [Article Influence: 12.7] [Reference Citation Analysis]
32 Mcphail GL, Acton JD, Fenchel MC, Amin RS, Seid M. Improvements in Lung Function Outcomes in Children with Cystic Fibrosis are Associated with Better Nutrition, Fewer Chronic Pseudomonas aeruginosa Infections, and Dornase Alfa Use. The Journal of Pediatrics 2008;153:752-7. [DOI: 10.1016/j.jpeds.2008.07.011] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 3.2] [Reference Citation Analysis]
33 Kraemer R, Blum A, Schibler A, Ammann RA, Gallati S. Ventilation Inhomogeneities in Relation to Standard Lung Function in Patients with Cystic Fibrosis. Am J Respir Crit Care Med 2005;171:371-8. [DOI: 10.1164/rccm.200407-948oc] [Cited by in Crossref: 105] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
34 Amadori A, Antonelli A, Balteri I, Schreiber A, Bugiani M, De Rose V. Recurrent exacerbations affect FEV(1) decline in adult patients with cystic fibrosis. Respir Med 2009;103:407-13. [PMID: 19027279 DOI: 10.1016/j.rmed.2008.09.024] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
35 Yoon JC. Evolving Mechanistic Views and Emerging Therapeutic Strategies for Cystic Fibrosis-Related Diabetes. J Endocr Soc 2017;1:1386-400. [PMID: 29264462 DOI: 10.1210/js.2017-00362] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
36 Costa M, Potvin S, Hammana I, Malet A, Berthiaume Y, Jeanneret A, Lavoie A, Lévesque R, Perrier J, Poisson D, Karelis AD, Chiasson JL, Rabasa-Lhoret R. Increased glucose excursion in cystic fibrosis and its association with a worse clinical status. J Cyst Fibros 2007;6:376-83. [PMID: 17409029 DOI: 10.1016/j.jcf.2007.02.005] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 3.7] [Reference Citation Analysis]
37 Wennström I, Berg U, Kornfält R, Rydén O. Gender affects self-evaluation in children with cystic fibrosis and their healthy siblings: CF, sibling pairs and self-evaluation. Acta Paediatrica 2005;94:1320-6. [DOI: 10.1111/j.1651-2227.2005.tb02094.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
38 Barr HL, Britton J, Smyth AR, Fogarty AW. Association between socioeconomic status, sex, and age at death from cystic fibrosis in England and Wales (1959 to 2008): cross sectional study. BMJ 2011;343:d4662. [PMID: 21862532 DOI: 10.1136/bmj.d4662] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 5.1] [Reference Citation Analysis]
39 Plummer A, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst Rev 2011;:CD006682. [PMID: 21249681 DOI: 10.1002/14651858.CD006682.pub3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
40 Silva IAL, Duarte A, Marson FAL, Centeio R, Doušová T, Kunzelmann K, Amaral MD. Assessment of Distinct Electrophysiological Parameters in Rectal Biopsies for the Choice of the Best Diagnosis/Prognosis Biomarkers for Cystic Fibrosis. Front Physiol 2020;11:604580. [PMID: 33424627 DOI: 10.3389/fphys.2020.604580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Rosenfeld M, Ramsey BW, Gibson RL. Pseudomonas acquisition in young patients with cystic fibrosis: pathophysiology, diagnosis, and management: . Current Opinion in Pulmonary Medicine 2003;9:492-7. [DOI: 10.1097/00063198-200311000-00008] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 4.3] [Reference Citation Analysis]
42 Cogen J, Emerson J, Sanders DB, Ren C, Schechter MS, Gibson RL, Morgan W, Rosenfeld M; EPIC Study Group. Risk factors for lung function decline in a large cohort of young cystic fibrosis patients. Pediatr Pulmonol 2015;50:763-70. [PMID: 26061914 DOI: 10.1002/ppul.23217] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 9.9] [Reference Citation Analysis]
43 Dagan A, Keller N, Vilozni D, Ramon-Saraf R, Bar BE, Sarouk I, Ashkenazi M, Lavie M, Efrati O. Nocardia Colonization: A Risk Factor for Lung Deterioration in Cystic Fibrosis Patients? Med Sci Monit 2015;21:1889-94. [PMID: 26125407 DOI: 10.12659/MSM.893643] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
44 Konstan MW, Morgan WJ, Butler SM, Pasta DJ, Craib ML, Silva SJ, Stokes DC, Wohl ME, Wagener JS, Regelmann WE, Johnson CA; Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007;151:134-9, 139.e1. [PMID: 17643762 DOI: 10.1016/j.jpeds.2007.03.006] [Cited by in Crossref: 292] [Cited by in F6Publishing: 276] [Article Influence: 19.5] [Reference Citation Analysis]
45 Thomsen K, Christophersen L, Bjarnsholt T, Jensen PØ, Moser C, Høiby N. Anti-Pseudomonas aeruginosa IgY Antibodies Induce Specific Bacterial Aggregation and Internalization in Human Polymorphonuclear Neutrophils. Infect Immun 2015;83:2686-93. [PMID: 25895968 DOI: 10.1128/IAI.02970-14] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
46 Bretones P. Question 4 Quelles stratégies diagnostiques et thérapeutiques des troubles du métabolisme glucidique au cours de la mucoviscidose? Stratégies diagnostiques et thérapeutiques des troubles du métabolisme glucidique au cours de la mucoviscidose. Archives de Pédiatrie 2003;10:475-86. [DOI: 10.1016/s0929-693x(03)90014-5] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
47 Simoneau T, Bazzaz O, Sawicki GS, Gordon C. Vitamin D status in children with cystic fibrosis. Associations with inflammation and bacterial colonization. Ann Am Thorac Soc. 2014;11:205-210. [PMID: 24423241 DOI: 10.1513/annalsats.201306-171bc] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
48 Hammana I, Potvin S, Tardif A, Berthiaume Y, Coderre L, Rabasa-lhoret R. Validation of insulin secretion indices in cystic fibrosis patients. Journal of Cystic Fibrosis 2009;8:378-81. [DOI: 10.1016/j.jcf.2009.08.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
49 Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003;168:918-951. [PMID: 14555458 DOI: 10.1164/rccm.200304-505so] [Cited by in Crossref: 1114] [Cited by in F6Publishing: 467] [Article Influence: 58.6] [Reference Citation Analysis]
50 Schick A, Kassen R. Rapid diversification of Pseudomonas aeruginosa in cystic fibrosis lung-like conditions. Proc Natl Acad Sci U S A 2018;115:10714-9. [PMID: 30275334 DOI: 10.1073/pnas.1721270115] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
51 Béghin L, Michaud L, Loeuille GA, Wizla-Derambure N, Sayah H, Sardet A, Thumerelle C, Deschildre A, Turck D, Gottrand F. Changes in lung function in young cystic fibrosis patients between two courses of intravenous antibiotics against Pseudomonas aeruginosa. Pediatr Pulmonol 2009;44:464-71. [PMID: 19360849 DOI: 10.1002/ppul.21017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
52 Shteinberg M, Downey DG, Beattie D, McCaughan J, Reid A, Stein N, Elborn JS. Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His. ERJ Open Res 2017;3:00056-2016. [PMID: 28845426 DOI: 10.1183/23120541.00056-2016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
53 Bienvenu T, Sermet-Gaudelus I, Burgel PR, Hubert D, Crestani B, Bassinet L, Dusser D, Fajac I. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2010;181:1078-84. [PMID: 20167849 DOI: 10.1164/rccm.200909-1434OC] [Cited by in Crossref: 57] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
54 Béghin L, Gottrand F, Michaud L, Vodougnon H, Wizla-derambure N, Hankard R, Husson M, Turck D. Energetic cost of physical activity in cystic fibrosis children during Pseudomonas aeruginosa pulmonary exacerbation. Clinical Nutrition 2005;24:88-96. [DOI: 10.1016/j.clnu.2004.07.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
55 Alicandro G, Bisogno A, Rota M, Padoan R, Colombo C. No gender differences in growth patterns in a cohort of children with cystic fibrosis born between 1986 and 1995. Clinical Nutrition 2019;38:1782-7. [DOI: 10.1016/j.clnu.2018.07.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Burggraeve N, Branger B, Dabadie A, Deneuville E, Rault G, Roussey M. Évolution des épreuves fonctionnelles respiratoires (EFR) chez des enfants atteints de mucoviscidose et dépistés à la naissance. Lien avec l'infection pulmonaire. Étude sur 40 enfants et 744 EFR. Archives de Pédiatrie 2007;14:864-9. [DOI: 10.1016/j.arcped.2007.02.089] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
57 Griffiths AL, Wurzel DF, Robinson PJ, Carzino R, Massie J. Australian epidemic strain pseudomonas (AES-1) declines further in a cohort segregated cystic fibrosis clinic. Journal of Cystic Fibrosis 2012;11:49-52. [DOI: 10.1016/j.jcf.2011.08.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
58 Ryall B, Carrara M, Zlosnik JE, Behrends V, Lee X, Wong Z, Lougheed KE, Williams HD. The mucoid switch in Pseudomonas aeruginosa represses quorum sensing systems and leads to complex changes to stationary phase virulence factor regulation. PLoS One 2014;9:e96166. [PMID: 24852379 DOI: 10.1371/journal.pone.0096166] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 3.5] [Reference Citation Analysis]
59 Sagel SD, Wagner BD, Anthony MM, Emmett P, Zemanick ET. Sputum biomarkers of inflammation and lung function decline in children with cystic fibrosis. Am J Respir Crit Care Med 2012;186:857-65. [PMID: 22904182 DOI: 10.1164/rccm.201203-0507OC] [Cited by in Crossref: 160] [Cited by in F6Publishing: 82] [Article Influence: 16.0] [Reference Citation Analysis]
60 Akkerman-Nijland AM, Akkerman OW, Grasmeijer F, Hagedoorn P, Frijlink HW, Rottier BL, Koppelman GH, Touw DJ. The pharmacokinetics of antibiotics in cystic fibrosis. Expert Opin Drug Metab Toxicol 2021;17:53-68. [PMID: 33213220 DOI: 10.1080/17425255.2021.1836157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
61 Pittman JE, Noah H, Calloway HE, Davis SD, Leigh MW, Drumm M, Sagel SD, Accurso FJ, Knowles MR, Sontag MK. Early childhood lung function is a stronger predictor of adolescent lung function in cystic fibrosis than early Pseudomonas aeruginosa infection. PLoS One 2017;12:e0177215. [PMID: 28505188 DOI: 10.1371/journal.pone.0177215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
62 Aigner C, Jaksch P, Seebacher G, Mazhar S, Wisser W, Klepetko W. Cystic fibrosis and lung transplantation — Determination of the survival benefit. Wien Klin Wochenschr 2004;116:318-21. [DOI: 10.1007/bf03040902] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
63 Li W, Soave D, Miller MR, Keenan K, Lin F, Gong J, Chiang T, Stephenson AL, Durie P, Rommens J, Sun L, Strug LJ. Unraveling the complex genetic model for cystic fibrosis: pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities. Hum Genet 2014;133:151-61. [PMID: 24057835 DOI: 10.1007/s00439-013-1363-7] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 7.8] [Reference Citation Analysis]
64 McGarry ME, Neuhaus JM, Nielson DW, Burchard E, Ly NP. Pulmonary function disparities exist and persist in Hispanic patients with cystic fibrosis: A longitudinal analysis. Pediatr Pulmonol 2017;52:1550-7. [PMID: 29082671 DOI: 10.1002/ppul.23884] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
65 Goldberg HJ, Deykin A. Advances in Lung Transplantation for Patients Who Have Cystic Fibrosis. Clinics in Chest Medicine 2007;28:445-57. [DOI: 10.1016/j.ccm.2007.02.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
66 Sousa M, Servidoni MF, Vinagre AM, Ramalho AS, Bonadia LC, Felício V, Ribeiro MA, Uliyakina I, Marson FA, Kmit A, Cardoso SR, Ribeiro JD, Bertuzzo CS, Sousa L, Kunzelmann K, Ribeiro AF, Amaral MD. Measurements of CFTR-mediated Cl- secretion in human rectal biopsies constitute a robust biomarker for Cystic Fibrosis diagnosis and prognosis. PLoS One 2012;7:e47708. [PMID: 23082198 DOI: 10.1371/journal.pone.0047708] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 4.2] [Reference Citation Analysis]
67 Mogayzel PJ, Naureckas ET, Robinson KA, Brady C, Guill M, Lahiri T, Lubsch L, Matsui J, Oermann CM, Ratjen F, Rosenfeld M, Simon RH, Hazle L, Sabadosa K, Marshall BC. Cystic Fibrosis Foundation Pulmonary Guideline*. Pharmacologic Approaches to Prevention and Eradication of Initial Pseudomonas aeruginosa Infection. Annals ATS 2014;11:1640-50. [DOI: 10.1513/annalsats.201404-166oc] [Cited by in Crossref: 128] [Cited by in F6Publishing: 56] [Article Influence: 16.0] [Reference Citation Analysis]
68 Tierney S, Riley D, Jones AM, Webb AK, Horne M. Sputum issues as defined by patients with cystic fibrosis: a qualitative investigation. Chronic Illn 2010;6:192-201. [PMID: 20634227 DOI: 10.1177/1742395310372812] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
69 Kraemer R, Latzin P, Pramana I, Ballinari P, Gallati S, Frey U. Long-term gas exchange characteristics as markers of deterioration in patients with cystic fibrosis. Respir Res 2009;10:106. [PMID: 19909502 DOI: 10.1186/1465-9921-10-106] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
70 Courtney JM, Bradley J, Mccaughan J, O'Connor TM, Shortt C, Bredin CP, Bradbury I, Elborn JS. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007;42:525-32. [PMID: 17469153 DOI: 10.1002/ppul.20619] [Cited by in Crossref: 103] [Cited by in F6Publishing: 96] [Article Influence: 6.9] [Reference Citation Analysis]
71 Solomon M, Mallory GB. Lung transplant referrals for individuals with cystic fibrosis: A pediatric perspective on the cystic fibrosis foundation consensus guidelines. Pediatr Pulmonol 2021;56:465-71. [PMID: 33300243 DOI: 10.1002/ppul.25215] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Rosanio FM, Mozzillo E, Cimbalo C, Casertano A, Sepe A, Raia V, Franzese A, Tosco A. Diabetes outbreak during COVID19 lock-down in a prediabetic patient with cystic fibrosis long treated with glargine. Ital J Pediatr 2021;47:121. [PMID: 34078438 DOI: 10.1186/s13052-021-01076-7] [Reference Citation Analysis]
73 Thomsen K, Christophersen L, Jensen PØ, Bjarnsholt T, Moser C, Høiby N. Anti-Pseudomonas aeruginosa IgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophils. Hum Vaccin Immunother 2016;12:1690-9. [PMID: 26901841 DOI: 10.1080/21645515.2016.1145848] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
74 Langan KM, Kotsimbos T, Peleg AY. Managing Pseudomonas aeruginosa respiratory infections in cystic fibrosis. Curr Opin Infect Dis. 2015;28:547-556. [PMID: 26524327 DOI: 10.1097/qco.0000000000000217] [Cited by in Crossref: 46] [Cited by in F6Publishing: 26] [Article Influence: 7.7] [Reference Citation Analysis]
75 Plummer A, Wildman M, Plummer A. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd006682.pub4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
76 Quintas S, Pereira L, Lito L, Barreto C. Perfil epidemiológico das infecções bacterianas do aparelho respiratório em doentes com fibrose quística. Revista Portuguesa de Pneumologia 2003;9:337-52. [DOI: 10.1016/s0873-2159(15)30683-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
77 Martín-frías M, Máiz L, Carcavilla A, Barrio R. Long-Term Benefits in Lung Function and Nutritional Status of Strict Metabolic Control of Cystic Fibrosis-Related Diabetes. Archivos de Bronconeumología (English Edition) 2011;47:531-4. [DOI: 10.1016/j.arbr.2011.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
78 Com G, Carroll JL, Castro MM, Tang X, Jambhekar S, Berlinski A. Predictors and outcome of low initial forced expiratory volume in 1 second measurement in children with cystic fibrosis. J Pediatr 2014;164:832-8. [PMID: 24418473 DOI: 10.1016/j.jpeds.2013.11.064] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
79 Walker TS, Tomlin KL, Worthen GS, Poch KR, Lieber JG, Saavedra MT, Fessler MB, Malcolm KC, Vasil ML, Nick JA. Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect Immun 2005;73:3693-701. [PMID: 15908399 DOI: 10.1128/IAI.73.6.3693-3701.2005] [Cited by in Crossref: 169] [Cited by in F6Publishing: 95] [Article Influence: 9.9] [Reference Citation Analysis]
80 Stuart B, Lin JH, Mogayzel PJ Jr. Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis. Paediatr Respir Rev 2010;11:177-84. [PMID: 20692633 DOI: 10.1016/j.prrv.2010.05.003] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 4.6] [Reference Citation Analysis]
81 Pincikova T, Nilsson K, Moen IE, Karpati F, Fluge G, Hollsing A, Knudsen PK, Lindblad A, Mared L, Pressler T. Inverse relation between vitamin D and serum total immunoglobulin G in the Scandinavian Cystic Fibrosis Nutritional Study. Eur J Clin Nutr. 2011;65:102-109. [PMID: 20859300 DOI: 10.1038/ejcn.2010.194] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
82 Alhede M, Bjarnsholt T, Givskov M, Alhede M. Pseudomonas aeruginosa biofilms: mechanisms of immune evasion. Adv Appl Microbiol 2014;86:1-40. [PMID: 24377853 DOI: 10.1016/B978-0-12-800262-9.00001-9] [Cited by in Crossref: 103] [Cited by in F6Publishing: 49] [Article Influence: 12.9] [Reference Citation Analysis]
83 Moran A, Brunzell C, Cohen RC, Katz M, Marshall BC, Onady G, Robinson KA, Sabadosa KA, Stecenko A, Slovis B; CFRD Guidelines Committee. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33:2697-2708. [PMID: 21115772 DOI: 10.2337/dc10-1768] [Cited by in Crossref: 382] [Cited by in F6Publishing: 286] [Article Influence: 34.7] [Reference Citation Analysis]
84 Griffiths AL, Jamsen K, Carlin JB, Grimwood K, Carzino R, Robinson PJ, Massie J, Armstrong DS. Effects of Segregation on an Epidemic Pseudomonas aeruginosa Strain in a Cystic Fibrosis Clinic. Am J Respir Crit Care Med 2005;171:1020-5. [DOI: 10.1164/rccm.200409-1194oc] [Cited by in Crossref: 65] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
85 Ehsan Z, Wetzel JD, Clancy JP. Nebulized liposomal amikacin for the treatment of Pseudomonas aeruginosa infection in cystic fibrosis patients. Expert Opin Investig Drugs 2014;23:743-9. [PMID: 24597573 DOI: 10.1517/13543784.2014.895322] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
86 Riethmueller J, Junge S, Schroeter TW, Kuemmerer K, Franke P, Ballmann M, Claass A, Broemme S, Jeschke R, Hebestreit A, Staab D, Koetz K, Doering G, Stern M. Continuous vs thrice-daily ceftazidime for elective intravenous antipseudomonal therapy in cystic fibrosis. Infection 2009;37:418-23. [DOI: 10.1007/s15010-009-8116-5] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
87 Stoltz DA, Ozer EA, Ng CJ, Yu JM, Reddy ST, Lusis AJ, Bourquard N, Parsek MR, Zabner J, Shih DM. Paraoxonase-2 deficiency enhances Pseudomonas aeruginosa quorum sensing in murine tracheal epithelia. Am J Physiol Lung Cell Mol Physiol 2007;292:L852-60. [PMID: 17122353 DOI: 10.1152/ajplung.00370.2006] [Cited by in Crossref: 101] [Cited by in F6Publishing: 92] [Article Influence: 6.3] [Reference Citation Analysis]
88 Akkerman-Nijland AM, Yousofi M, Rottier BL, Van der Vaart H, Burgerhof JGM, Frijlink HW, Touw DJ, Koppelman GH, Akkerman OW. Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin. Ther Adv Respir Dis 2020;14:1753466620905279. [PMID: 32046620 DOI: 10.1177/1753466620905279] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
89 Burrus TE, Vogt H, Pettit RS. Impact of a pharmacy technician and pharmacist on time to inhaled tobramycin therapy in a pediatric cystic fibrosis clinic. Pediatr Pulmonol 2021;56:2861-7. [PMID: 34191410 DOI: 10.1002/ppul.25554] [Reference Citation Analysis]
90 Psoter KJ, De Roos AJ, Wakefield J, Mayer JD, Rosenfeld M. Seasonality of acquisition of respiratory bacterial pathogens in young children with cystic fibrosis. BMC Infect Dis 2017;17:411. [PMID: 28599639 DOI: 10.1186/s12879-017-2511-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
91 Carlsson M, Shukla S, Petersson AC, Segelmark M, Hellmark T. Pseudomonas aeruginosa in cystic fibrosis: pyocyanin negative strains are associated with BPI-ANCA and progressive lung disease. J Cyst Fibros 2011;10:265-71. [PMID: 21463973 DOI: 10.1016/j.jcf.2011.03.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
92 Martín-Frías M, Lamas Ferreiro A, Colino Alcol E, Alvarez Gómez MA, Yelmo Valverde R, Barrio Castellanos R. [Continuous glucose monitoring system in the screening of glucose disorders in cystic fibrosis]. An Pediatr (Barc) 2009;70:120-5. [PMID: 19217566 DOI: 10.1016/j.anpedi.2008.10.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
93 Harun SN, Wainwright C, Klein K, Hennig S. A systematic review of studies examining the rate of lung function decline in patients with cystic fibrosis. Paediatr Respir Rev. 2016;20:55-66. [PMID: 27259460 DOI: 10.1016/j.prrv.2016.03.002] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 5.2] [Reference Citation Analysis]
94 Fernandes B, Plummer A, Wildman M. Duration of intravenous antibiotic therapy in people with cystic fibrosis. Cochrane Database Syst Rev 2008;:CD006682. [PMID: 18425963 DOI: 10.1002/14651858.CD006682.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
95 Horsley A. Lung clearance index in the assessment of airways disease. Respiratory Medicine 2009;103:793-9. [DOI: 10.1016/j.rmed.2009.01.025] [Cited by in Crossref: 88] [Cited by in F6Publishing: 84] [Article Influence: 6.8] [Reference Citation Analysis]
96 VanDyke RD, McPhail GL, Huang B, Fenchel MC, Amin RS, Carle AC, Chini BA, Seid M. Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis. Ann Am Thorac Soc 2013;10:205-12. [PMID: 23802816 DOI: 10.1513/AnnalsATS.201209-082OC] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
97 Goeminne PC, Nawrot TS, De Boeck K, Nemery B, Dupont LJ. Proximity to blue spaces and risk of infection with Pseudomonas aeruginosa in cystic fibrosis: A case-control analysis. J Cyst Fibros 2015;14:741-7. [PMID: 25940953 DOI: 10.1016/j.jcf.2015.04.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
98 Girón Moreno RM, García-Clemente M, Diab-Cáceres L, Martínez-Vergara A, Martínez-García MÁ, Gómez-Punter RM. Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review. Antibiotics (Basel) 2021;10:486. [PMID: 33922413 DOI: 10.3390/antibiotics10050486] [Reference Citation Analysis]
99 Rosenfeld M, Vandevanter DR, Ren CL, Elkin EP, Pasta DJ, Konstan MW, Morgan WJ; for the Investigators of Coordinators of the Epidemiologic Study of Cystic Fibrosis. Decline in lung function does not predict future decline in lung function in cystic fibrosis patients: Lung Function Decline in Cystic Fibrosis. Pediatr Pulmonol 2015;50:856-62. [DOI: 10.1002/ppul.23227] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
100 Welsh L, Robertson CF, Ranganathan SC. Increased rate of lung function decline in Australian adolescents with cystic fibrosis: Increased Rate of Lung Function. Pediatr Pulmonol 2014;49:873-7. [DOI: 10.1002/ppul.22946] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
101 Moskowitz SM, Chmiel JF, Sternen DL, Cheng E, Gibson RL, Marshall SG, Cutting GR. Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders. Genet Med. 2008;10:851-868. [PMID: 19092437 DOI: 10.1097/gim.0b013e31818e55a2] [Cited by in Crossref: 85] [Cited by in F6Publishing: 41] [Article Influence: 6.5] [Reference Citation Analysis]
102 Mozzillo E, Franzese A, Valerio G, Sepe A, De Simone I, Mazzarella G, Ferri P, Raia V. One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements. Pediatric Diabetes 2009;10:162-7. [DOI: 10.1111/j.1399-5448.2008.00451.x] [Cited by in Crossref: 67] [Cited by in F6Publishing: 52] [Article Influence: 5.2] [Reference Citation Analysis]
103 Cutting GR. Cystic Fibrosis. Emery and Rimoin's Principles and Practice of Medical Genetics. Elsevier; 2013. pp. 1-54. [DOI: 10.1016/b978-0-12-383834-6.00062-8] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
104 Mogayzel PJ, Dunitz J, Marrow LC, Hazle LA. Improving chronic care delivery and outcomes: the impact of the cystic fibrosis Care Center Network. BMJ Qual Saf 2014;23:i3-8. [DOI: 10.1136/bmjqs-2013-002363] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 5.0] [Reference Citation Analysis]
105 Coffey MJ, Whitaker V, Gentin N, Junek R, Shalhoub C, Nightingale S, Hilton J, Wiley V, Wilcken B, Gaskin KJ, Ooi CY. Differences in Outcomes between Early and Late Diagnosis of Cystic Fibrosis in the Newborn Screening Era. J Pediatr 2017;181:137-145.e1. [PMID: 27837951 DOI: 10.1016/j.jpeds.2016.10.045] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.7] [Reference Citation Analysis]
106 Pascoal MA, Marson FAL, Paschoal IA, Levy CE. Influence of pancreatic status, CFTR mutations, Staphylococcus aureus and/or Pseudomonas aeruginosa infection/colonization on lung function in cystic fibrosis during a 2-year follow-up period. Wien Klin Wochenschr 2020;132:572-80. [PMID: 32356101 DOI: 10.1007/s00508-020-01660-7] [Reference Citation Analysis]
107 Bashir G, Bhat JI, Mohammad S, Fomda BA, Bali NK, Altaf I. Airway Microbiology in Children with Cystic Fibrosis: A Prospective Cohort Study from Northern India. J Trop Pediatr 2021;67:fmab030. [PMID: 34100087 DOI: 10.1093/tropej/fmab030] [Reference Citation Analysis]
108 Madan JC, Koestler DC, Stanton BA, Davidson L, Moulton LA, Housman ML, Moore JH, Guill MF, Morrison HG, Sogin ML. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. MBio. 2012;3:pii: e00251-12. [PMID: 22911969 DOI: 10.1128/mbio.00251-12] [Cited by in Crossref: 192] [Cited by in F6Publishing: 120] [Article Influence: 19.2] [Reference Citation Analysis]
109 Vantyghem M, Moussaïd-guennoun R, Perimenis P, Marcelli-tourvieille S, Perez T, Wallaert B. Le diabète de la mucoviscidose chez l’adulte. Annales d'Endocrinologie 2005;66:347-54. [DOI: 10.1016/s0003-4266(05)81792-5] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
110 Davis PB, Schluchter MD, Konstan MW. Relation of sweat chloride concentration to severity of lung disease in cystic fibrosis. Pediatr Pulmonol 2004;38:204-9. [PMID: 15274098 DOI: 10.1002/ppul.20054] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
111 Jablonski L, Lee CKK, Rosenstein BJ, Mogayzel PJ Jr, Paranjape S, Pan A. Real World Experience of Pseudomonas aeruginosa Eradication at an Urban Pediatric Cystic Fibrosis Center. J Pediatr Pharmacol Ther 2020;25:623-8. [PMID: 33041717 DOI: 10.5863/1551-6776-25.7.623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
112 Simanovsky N, Cohen-Cymberknoh M, Shoseyov D, Gileles-Hillel A, Wilschanski M, Kerem E, Hiller N. Differences in the pattern of structural abnormalities on CT scan in patients with cystic fibrosis and pancreatic sufficiency or insufficiency. Chest 2013;144:208-14. [PMID: 23392565 DOI: 10.1378/chest.12-1226] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
113 Behrends V, Ryall B, Zlosnik JEA, Speert DP, Bundy JG, Williams HD. Metabolic adaptations of Pseudomonas aeruginosa during cystic fibrosis chronic lung infections: Metabolomic adaptations of cystic fibrosis isolates. Environ Microbiol 2013;15:398-408. [DOI: 10.1111/j.1462-2920.2012.02840.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 53] [Article Influence: 5.0] [Reference Citation Analysis]
114 Dennersten U, Lannefors L, Höglund P, Hellberg K, Johansson H, Lagerkvist A, Ortfelt M, Sahlberg M, Eriksson L. Lung function in the aging Swedish cystic fibrosis population. Respiratory Medicine 2009;103:1076-82. [DOI: 10.1016/j.rmed.2009.01.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
115 Pasterkamp H, Menzies KJ, Bayomi DJ. Cystic fibrosis in Canadian Hutterites. Pediatr Pulmonol 2019;55:526-32. [DOI: 10.1002/ppul.24590] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
116 Matsui H, Wagner VE, Hill DB, Schwab UE, Rogers TD, Button B, Taylor RM 2nd, Superfine R, Rubinstein M, Iglewski BH, Boucher RC. A physical linkage between cystic fibrosis airway surface dehydration and Pseudomonas aeruginosa biofilms. Proc Natl Acad Sci U S A 2006;103:18131-6. [PMID: 17116883 DOI: 10.1073/pnas.0606428103] [Cited by in Crossref: 153] [Cited by in F6Publishing: 133] [Article Influence: 9.6] [Reference Citation Analysis]
117 Ehsan Z, Clancy JP. Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin. Future Microbiol 2015;10:1901-12. [PMID: 26573178 DOI: 10.2217/fmb.15.117] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
118 Thorn ST, Brown MA, Yanes JJ, Sherrill DL, Pugmire J, Anderson KA, Klotz SA. Pulmonary nocardiosis in cystic fibrosis. Journal of Cystic Fibrosis 2009;8:316-20. [DOI: 10.1016/j.jcf.2009.07.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
119 McManus TE, McDowell A, Moore JE, Elborn SJ. Organisms isolated from adults with cystic fibrosis. Ann Clin Microbiol Antimicrob 2004;3:26. [PMID: 15601468 DOI: 10.1186/1476-0711-3-26] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
120 Parks QM, Young RL, Poch KR, Malcolm KC, Vasil ML, Nick JA. Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapy. J Med Microbiol 2009;58:492-502. [PMID: 19273646 DOI: 10.1099/jmm.0.005728-0] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 5.3] [Reference Citation Analysis]
121 Farrell PM, Collins J, Broderick LS, Rock MJ, Li Z, Kosorok MR, Laxova A, Gershan WM, Brody AS. Association between mucoid Pseudomonas infection and bronchiectasis in children with cystic fibrosis. Radiology 2009;252:534-43. [PMID: 19703887 DOI: 10.1148/radiol.2522081882] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
122 Mohan K, Israel KL, Miller H, Grainger R, Ledson MJ, Walshaw MJ. Long-Term Effect of Insulin Treatment in Cystic Fibrosis-Related Diabetes. Respiration 2008;76:181-6. [DOI: 10.1159/000110206] [Cited by in Crossref: 62] [Cited by in F6Publishing: 50] [Article Influence: 4.4] [Reference Citation Analysis]